President Donald Trump announced Friday that a second pharmaceutical corporation caved to his demands on drug pricing and U.S.-based manufacturing.
The deal with AstraZeneca, which is based in the U.K., includes a “most-favored-nation” pricing model that Trump has said will lower prescription costs for Americans, including those on Medicaid. AstraZeneca will also make its drugs available through a new federal website Trump announced last month, TrumpRx.gov, said the president.
AstraZeneca will also invest $50 billion in drug manufacturing and research and development in the U.S. as part of the deal with the Trump administration.